ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅.
ΠΡΠ΅Π΄ΡΠΏΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°Ρ
Π°ΡΠ½ΡΠΌ Π΄ΠΈΠ°Π±Π΅ΡΠΎΠΌ Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΠ΅ΠΉ
ΠΠΎΠΌΠΈΡΠ΅Ρ ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ². Π Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ΅, Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ. ΠΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡ 2002; ΠΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅. Hansson L., Zanchetti A., Carruthers SG. et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755β62. Brown… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠ΅Π΄ΡΠΏΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°Ρ Π°ΡΠ½ΡΠΌ Π΄ΠΈΠ°Π±Π΅ΡΠΎΠΌ Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΠ΅ΠΉ (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
ΠΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΡ ΡΠ°ΡΡΠΎ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π΅Ρ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π‘Π. ΠΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ ΡΡΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Π²ΠΏΠΎΠ»Π½Π΅ ΡΠ΅Π°Π»ΡΠ½Π°. ΠΠ½Π° Π·Π°ΠΊΠ»ΡΡΠ°Π΅ΡΡΡ Π² ΠΆΠ΅ΡΡΠΊΠΎΠΌ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ Π·Π° ΡΠ΅Π»ΡΠΌ ΡΡΠ΄ΠΎΠΌ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΡ ΡΡΠΆΠ΅ΡΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΉ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ — ΡΡΠΎΠ²Π΅Π½Ρ ΠΠ, Π»ΠΈΠΏΠΈΠ΄Π½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ, ΡΡΠΎΠ²Π΅Π½Ρ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΠΈ, ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΡ ΠΈ Π΄Ρ. ΠΠ»Ρ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΈ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΠΠ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π‘Π 2 ΡΠΈΠΏΠ° ΠΌΠΎΠ³ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡΡΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π²ΡΠ΅ ΠΊΠ»Π°ΡΡΡ Π°Π½ΡΠΈΠ³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ²Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ², ΡΠ°ΡΡΠΎ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡΡ .
ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- 1. Zimmet P. Globalization< coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Mad 2000; 247: 301−310.
- 2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703−13.
- 3. Stamler J., Vaccaro O., Neaton JD, Wentworth D., for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434−444.
- 4. Haffner M., Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with 2 diabetes and in nondiabetic subjects with and without prior myocardial infaction. N. Engl. J. Med., 1999, 339, 229−234.
- 5. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. An Update. Hypertension 2001; 37: 1053−1059.
- 6. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905−912.
- 7. Parving H-H. Hypertension and diabetes: the scope of the problem. Blood pressure 2001; 10 (Suppl 2): 25−31.
- 8. Cooper M. The prevalence of hypertension in patients with diabetes. In: Hypertension and diabetes (Ed. Mogensen CE). Lippincott Williams & Wilkins, London, 2003, 3−9.
- 9. Guidelines Committee. 2003 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011−1053.
- 10. Rocchini AP. Obesity hypertension, salt sensitivity and insulin resistance. Nutr Metab Cardiovasc Dis 2000; 10: 287−294.
- 11. Hansson L., Zanchetti A., Carruthers SG. et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755−62.
- 12. Guidelines Subcommitte. 1999 World Health Organization — International Society of Hypertension guidelines for the management of hypertension. J. Hypertension, 1999, 17(2), 151−183.
- 13. ΠΠΎΠΌΠΈΡΠ΅Ρ ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ². Π Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ΅, Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ. ΠΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡ 2002; ΠΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅.
- 14. The 7th report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003; 289: 2560−2572.
- 15. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20: 2099;2110.
- 16. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981−2997
- 17. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: INSIGHT. Lancet 2000; 356: 366−372.
- 18. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995−1003.
- 19. ΠΠ΅Π΄ΠΎΠ² Π. Π., Π¨Π΅ΡΡΠ°ΠΊΠΎΠ²Π° Π. Π. ΠΠΈΠ°Π±Π΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π½Π΅ΡΡΠΎΠΏΠ°ΡΠΈΡ. Π£Π½ΠΈΠ²Π΅ΡΡΡΠΌ ΠΠ°Π±Π»ΠΈΡΠΈΠ½Π³, ΠΠΎΡΠΊΠ²Π°, 2000, 240Ρ.
- 20. Califf RM. Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J Supplements 2003; 5(Suppl C): C13-C18.
- 21. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854−64.
- 22. Sever PS, Dahlof B, Poulter NR, et al for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149−1158.